Item Type | Name |
Concept
|
Costs and Cost Analysis
|
Concept
|
Drug Costs
|
Concept
|
Cost Savings
|
Concept
|
Health Care Costs
|
Concept
|
Cost-Benefit Analysis
|
Concept
|
Hospital Costs
|
Concept
|
Cost of Illness
|
Concept
|
Cost Control
|
Academic Article
|
Toxicity and costs of toxicity associated with new cancer drugs: international implications.
|
Academic Article
|
Estimating the cost effectiveness of atovaquone versus intravenous pentamidine in the treatment of mild-to-moderate Pneumocystis carinii pneumonia.
|
Academic Article
|
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease.
|
Academic Article
|
Medical care costs of intravenous drug users with AIDS in Brooklyn.
|
Academic Article
|
Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials.
|
Academic Article
|
Granulocyte-macrophage colony-stimulating factor as adjunct therapy in relapsed lymphoid malignancy: implications for economic analyses of phase III clinical trials.
|
Academic Article
|
Costs of care and outcomes for high-dose therapy and autologous transplantation for lymphoid malignancies: results from the University of Nebraska 1987 through 1991.
|
Academic Article
|
Estimating the cost effectiveness of total androgen blockade with flutamide in M1 prostate cancer.
|
Academic Article
|
The effect of reimbursement policies on the management of Medicare patients with refractory ovarian cancer.
|
Academic Article
|
Economic analysis in phase III clinical cancer trials.
|
Academic Article
|
Economic analysis during phase III clinical trials: who, what, when, where, and why?
|
Academic Article
|
Performance measurement in prostate cancer care: beyond report cards.
|
Academic Article
|
Cost-effective models for flutamide for prostate carcinoma patients: are they helpful to policy makers?
|
Academic Article
|
A review of the costs, cost-effectiveness and third-party charges of bone marrow transplantation.
|
Academic Article
|
Economic analyses of new technologies: the case of stem-cell transplantation.
|
Academic Article
|
Treatment considerations for persons with metastatic prostate cancer: survival versus out-of-pocket costs.
|
Academic Article
|
Health care economics and bone marrow transplantation.
|
Academic Article
|
Economic analyses of phase III cooperative cancer group clinical trials: are they feasible?
|
Academic Article
|
Treating malignant pleural effusions cost consciously.
|
Academic Article
|
Cancer insurance policies in Japan and the United States.
|
Academic Article
|
Economic analyses of bone marrow and blood stem cell transplantation for leukemias and lymphoma: what do we know?
|
Academic Article
|
Cost-effectiveness analysis comparing liposomal anthracyclines in the treatment of AIDS-related Kaposi's sarcoma.
|
Academic Article
|
Health economics in the treatment of colorectal cancer.
|
Academic Article
|
Cost-effectiveness model of a phase II clinical trial of a new pharmaceutical for essential thrombocythemia: is it helpful to policy makers?
|
Academic Article
|
Cost analyses of adjunct colony stimulating factors for older patients with acute myeloid leukaemia : can they improve clinical decision making?
|
Academic Article
|
Cost analyses of granulocyte colony stimulating factor: a focus on older patients with cancer.
|
Academic Article
|
Use of erythropoietin in cancer patients: assessment of oncologists' practice patterns in the United States and other countries.
|
Academic Article
|
Cost minimization study of image-guided core biopsy versus surgical excisional biopsy for women with abnormal mammograms.
|
Academic Article
|
The financial burden of cancer: estimates from a study of insured women with breast cancer.
|
Academic Article
|
Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000.
|
Academic Article
|
Pharmacoeconomics of liposomal anthracycline therapy.
|
Academic Article
|
Granulocyte colony--stimulating factor for chemotherapy-induced neutropenia in patients with small cell lung cancer : the 40% rule revisited.
|
Academic Article
|
Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening among Veterans.
|
Academic Article
|
Local perspective of the impact of the HIPAA privacy rule on research.
|
Academic Article
|
When the risk of febrile neutropenia is 20%, prophylactic colony-stimulating factor use is clinically effective, but is it cost-effective?
|
Academic Article
|
Responding to a small-scale bioterrorist anthrax attack: cost-effectiveness analysis comparing preattack vaccination with postattack antibiotic treatment and vaccination.
|
Academic Article
|
Evaluating the total costs of chemotherapy-induced febrile neutropenia: results from a pilot study with community oncology cancer patients.
|
Academic Article
|
Cost considerations in the management of cancer in the older patient.
|
Academic Article
|
Cancer-associated neutropenic fever: clinical outcome and economic costs of emergency department care.
|
Academic Article
|
Costs and cost-effectiveness of a low-intensity patient-directed intervention to promote colorectal cancer screening.
|
Academic Article
|
Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center.
|
Academic Article
|
Upping recruitment in clinical trials: are the costs worth it?
|
Academic Article
|
Costs and cost effectiveness of a health care provider-directed intervention to promote colorectal cancer screening.
|
Academic Article
|
The excessive cost of early stage bladder cancer care: are providers really to blame?
|
Academic Article
|
Cost-effectiveness comparison of response strategies to a large-scale anthrax attack on the chicago metropolitan area: impact of timing and surge capacity.
|
Academic Article
|
Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis.
|
Academic Article
|
Improving colon cancer screening in community clinics.
|
Academic Article
|
Strategies to improve repeat fecal occult blood testing cancer screening.
|
Academic Article
|
Erythropoietin, a novel repurposed drug: an innovative treatment for wound healing in patients with diabetes mellitus.
|
Academic Article
|
Economics of Malignant Gliomas: A Critical Review.
|
Academic Article
|
Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490).
|
Academic Article
|
Cost-effectiveness models of clinical trials of new pharmaceuticals for AIDS-related Pneumocystis carinii pneumonia: are they helpful to policy makers?
|
Academic Article
|
Sustaining mammography screening among the medically underserved: a follow-up evaluation.
|
Academic Article
|
Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment.
|
Academic Article
|
Relationship of Industry Sponsorship to Results of Cost-Effectiveness Analyses of Drugs Used in Breast Cancer Treatment--Reply.
|
Academic Article
|
Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door.
|
Academic Article
|
Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
|
Academic Article
|
Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia.
|
Academic Article
|
Biosimilars-Curb Your Enthusiasm.
|
Academic Article
|
Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.
|
Academic Article
|
Biosimilar Filgrastim Use in the United States vs the European Union and Japan-Why Does It Lag Behind and What Can Be Done?
|
Academic Article
|
Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada.
|
Academic Article
|
Pharmacoeconomics of amifostine in ovarian cancer.
|
Academic Article
|
Valuing clinical strategies early in development: a cost analysis of allogeneic peripheral blood stem cell transplantation.
|
Academic Article
|
Costs of care associated with high-dose therapy and autologous transplantation for non-Hodgkin's lymphoma: results from the University of Nebraska Medical Center 1989 to 1995.
|
Academic Article
|
Evaluation of conflict of interest in economic analyses of new drugs used in oncology.
|
Academic Article
|
Cost analysis of second-line therapies for platinum-refractory ovarian cancer: reimbursement dilemmas for Medicare patients.
|
Academic Article
|
The association between physician reimbursement in the US and use of hematopoietic colony stimulating factors as adjunct therapy for older patients with acute myeloid leukemia: results from the 1997 American Society of Clinical Oncology survey. Health Services Research Committee of the American Society of Clinical Oncology.
|
Academic Article
|
Does reimbursement affect physician decision making?
|
Academic Article
|
Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials.
|
Academic Article
|
Cost-effectiveness analysis of pegylated-liposomal doxorubicin and liposomal daunorubicin treatments in patients with Kaposi's sarcoma.
|
Academic Article
|
The potential for treatment of idiopathic thrombocytopenic purpura with anti-D to prevent splenectomy: a predictive cost analysis.
|
Academic Article
|
Cost analyses of adjunct colony stimulating factors for acute leukemia: can they improve clinical decision making.
|
Academic Article
|
Comparing cost-effectiveness analyses for the clinical oncology setting: the example of the Gynecologic Oncology Group 111 trial.
|
Academic Article
|
Purchasing oncology services. Kerr L. White Institute/American Cancer Society Task Force on Purchasing Oncology Services.
|
Academic Article
|
Evaluating the financial impact of clinical trials in oncology: results from a pilot study from the Association of American Cancer Institutes/Northwestern University clinical trials costs and charges project.
|
Academic Article
|
Comparative study of the clinical efficacy of two dosing regimens of flutamide.
|
Academic Article
|
Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer.
|
Academic Article
|
Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology.
|
Academic Article
|
Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.
|
Academic Article
|
Pricing, profits and pharmacoeconomics--for whose benefit?
|
Academic Article
|
Costs of terminal care for people with AIDS.
|
Academic Article
|
Clinical trials: are they a good buy?
|
Academic Article
|
Cost-effectiveness considerations in the treatment of essential thrombocythemia.
|
Academic Article
|
Evaluating the total costs of cancer. The Northwestern University Costs of Cancer Program.
|
Academic Article
|
Humira: the first $20 billion drug.
|